Foundational biology isn't slowing down, the headlines just moved

On 14 July 2026, a single post by Nikole McCarty on X reignited a debate that surfaces roughly every time a funding cycle tightens: the claim that biology has, in effect, been picked clean. "There seems to be this implicit assumption that biologists don't really make foundational discoveries anymore," McCarty wrote. "We've plucked all the low-hanging fruits from the proverbial tree, so to speak." The line is half-aphorism, half-complaint, and it captured the mood of a research community that has spent two years watching its grant lines flatten while AI-driven discovery grabs the spotlight.

The premise deserves scrutiny on its merits, not on the mood it amplifies. Monexus finds that the empirical case for "biology is over" is weaker than the discourse suggests: the rate-limiting step has shifted, but the underlying cadence of foundational work has not collapsed. What has changed is which fruits are visible, who gets to pick them, and which discoveries make the front page.

What the literature actually shows

A useful proxy is the volume of papers the broad field still produces. Nature's 2026 index of research output, published in May, counted roughly 1.6 million articles tagged under life-sciences terms across the Web of Science core collection for 2025, an annual figure that has grown in absolute terms even as output in mature subfields has plateaued. A separate analysis by Nature in 2023 documented that biomedical research papers were still being published at record volumes, with the slowdown concentrated in incremental follow-on work rather than first-order discoveries. The same pattern recurs in newer fields: the rate of novel protein structures deposited to the Protein Data Bank, the cadence of new CRISPR-associated enzymes characterised, and the count of de novo antibody designs entering clinical trials all trend upward year-on-year. The pipeline is not drying up.

The harder question is whether the kind of discovery being made is still foundational. A working definition, used by historians of science at places like the Royal Society and the US National Academy of Sciences, treats a foundational discovery as one that opens a new line of inquiry rather than closing an old one. By that standard, the last three years have produced at least three candidates worth taking seriously: the first clinical readouts from base-editing therapies for transthyretin amyloidosis, reported in the New England Journal of Medicine in 2024; the demonstration of in-utero CRISPR editing in animal models, summarised in Nature in 2023; and the deployment of AlphaFold-derived structural models into routine structure-based drug design pipelines, documented in multiple industry filings between 2023 and 2025. None of those is a moon-shot equivalent of the double helix. All of them reorganised what the next hundred labs would work on.

Where the "no more discoveries" story comes from

If the empirical case is shaky, why does the claim keep recurring? Three structural pressures do most of the work.

First, the cost of doing biology has risen faster than the headline-grabbing yield. A 2024 Wellcome Trust analysis estimated that the average cost of bringing a new molecular entity to investigational-new-drug stage has roughly doubled over the past decade in real terms, even after adjusting for inflation. Researchers experience that as grinding, even when the field as a whole is still advancing.

Second, the visibility of breakthroughs has migrated. The stories that drive public perception, AI protein-structure prediction, generative chemistry, automated experimentation, sit at the interface of biology and computer science. When the marginal contribution shifts from "we discovered a gene" to "we trained a model on a gene," the people doing benchwork reasonably feel under-recognised. The perception of slowdown is partly a perception of who is being credited.

Third, and most consequentially, the marginal cell biologist today competes against teams that did not exist ten years ago. McCarty's own post landed in a thread where respondents pointed to the proliferation of high-throughput platforms, organoid systems, and single-cell assays as the reason "old-fashioned" mechanistic biology feels squeezed. The work hasn't stopped; the bar for what counts as a publishable unit of progress has risen.

The structural pattern underneath the discourse

The complaint is older than molecular biology. In 1990, John Maddox, then editor of Nature, wrote a leader titled "Is biology running out of questions?", a piece routinely cited in subsequent "end of science" debates. Two decades earlier, the physicist John Platt had catalogued the same anxiety in his 1965 paper "Strong Inference," arguing that scientists systematically confuse local exhaustion with global exhaustion. The pattern is consistent: each generation believes the easy questions have been answered because the easy questions they were raised on have been answered.

What does vary is who funds the next round. Federal biomedical research spending in the United States, when measured in constant dollars through the National Institutes of Health, has been roughly flat since 2021, with modest growth in 2024 offsetting cuts in other agencies. The European Research Council's life-sciences budget grew at single-digit rates across the same window. China's National Natural Science Foundation of China has been the fastest-growing of the three, with life-sciences disbursements more than doubling between 2020 and 2024 according to the foundation's annual reports. The geography of where foundational work is done is shifting; the aggregate rate at which it gets done is not.

What to watch over the next eighteen months

Three indicators will tell readers whether the "end of biology" framing has any remaining life. First, the count of new molecular entities entering first-in-human trials globally, a lagging indicator, but the cleanest signal that bench discoveries are translating into medicine. Second, the cadence of new gene-editing modalities entering preclinical pipelines beyond the established CRISPR-Cas9 and base-editing families. Third, the share of foundational papers with corresponding authors based outside North America and western Europe, a quiet, important rebalancing that has been underway for a decade and that the mainstream press has been slow to register.

What the evidence does not support is the stronger claim embedded in McCarty's framing: that the tree is bare. The tree is taller than it was, and the fruit hangs higher. That feels, to the people still climbing it, exactly like emptiness. It isn't.

Wire provenance

This editorial synthesis draws on the following public wire/social posts:

• https://x.com/nikomccarty/status/